13 completed. 13 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 13 | Completed 13 |
| Phase 2 | 1 | Completed 1 |
Follow Transdermal Patch: new trials by email Literature Review of Transdermal Patch trials Research Report on Transdermal Patch
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Clinical Adhesion Study Between ZTlido 1.8% and Three Over-the-counter External Analgesic Lidocaine-containing Patches ZTlido (Lidocaine Topical System) 1.8%, Salonpas (Lidocaine Patch 4%), Aspercreme (Lidocaine Patch 4%) - Healthy | Phase 1 | Completed | Scilex Pharmaceuticals, Inc. | 24 | 2021-07-01 | 2021-11-03 |
| A Study of New Transdermal Contraceptive Patch at End of Shelf Life and Currently Marketed EVRA at the Beginning of Shelf Life in Healthy Women EVRA patch (NGMN+EE) (Treatment A) (Reference), High molecular weight polyisobutylene (HMW PIB) patch (NGMN+EE) (Treatment B) (Test) - Healthy | Phase 1 | Completed | Janssen Research & Development, LLC | 68 | 2019-07-12 | 2025-04-27 |
| Tolerability, Safety and Pharmacokinetics of a Topical AB001 Patch in Healthy Subjects AB001, oral capsule, positive comparative patch - Chronic Low Back Pain | Phase 1 | Completed | Frontier Biotechnologies Inc. | 34 | 2019-06-24 | 2020-03-30 |
| A Study of the Use of Microneedle Patches to Deliver Topical Lidocaine in the Oral Cavity Microneedle Patch, Patch with no microneedles - Topical Anaesthesia | Phase 1 | Completed | Innoture Ltd | 16 | 2018-07-31 | 2019-11-14 |
| Rivastigmine BA Trial With Multiple Application of Transdermal Patches, Adaptation and Tapering Phase RIV-TDS 13.3 mg/24 h, Exelon® 13.3 mg/24 hours transdermal patch - Bioequivalence | Phase 1 | Completed | SocraTec R&D GmbH | 36 | 2018-05-16 | 2018-08-21 |
| Micro Needle Array-Doxorubicin (MNA-D) in Patients With Cutaneous T-cell Lymphoma (CTCL) Micro needle array-Doxorubicin (MNA-D) - Cutaneous T Cell Lymphoma | Phase 1 | Completed | Falo, Louis, MD | 20 | 2016-03-09 | 2024-08-09 |
| Pharmacokinetic Study of Lidocaine Patch 1.8% Lidocaine Patch 5% (Lidoderm®) in Healthy Subjects Lidocaine patch 1.8%, Lidocaine 5% patch, Lidocaine 2% Injectable Solution - Healthy | Phase 1 | Completed | Scilex Pharmaceuticals, Inc. | 58 | 2014-04-28 | 2024-05-23 |
| Study to Evaluate Pharmacokinetics Profile, Wearability, and Safety of 2 Progestin-Only Patches levonorgestrel - Healthy | Phase 1 / Phase 2 | Completed | Agile Therapeutics | 36 | 2012-07-01 | 2018-01-23 |
| Smoking Termination / Anxiety Reduction Treatment (ST/ART) Nicotine Patch, Smoking Termination and Anxiety Reduction Treatment, Education-Supportive Psychotherapy - Smoking, Anxiety Disorders | Phase 1 | Completed | University of Houston | 74 | 2012-03-01 | 2019-04-23 |
| Pharmacokinetic Study Of AGILE AG200-15 After Weekly Application Under Various Conditions in Healthy Female Volunteers AG200-15 - Healthy | Phase 1 | Completed | Agile Therapeutics | 24 | 2011-05-01 | 2018-07-31 |
| Pharmacokinetic Study of Synera in Healthy Volunteers Synera - Healthy | Phase 1 | Completed | ZARS Pharma Inc. | 12 | 2010-02-01 | 2012-10-17 |
| Clinical Study in Healthy Men to Investigate the Uptake of Buprenorphine and Its Elimination From the Body After Dermal Application as Patches for 96 Hours and for 72 Hours Transtec 35 µg/hour transdermal patch - Pain, Pharmacokinetics | Phase 1 | Completed | Grünenthal GmbH | 30 | 2004-04-05 | 2018-12-10 |
| A Relative Bioavailability Study of Fentanyl 25 μg/h Transdermal System Fentanyl 25 μg/h transdermal system, single application, Duragesic 25 μg/h transdermal system single application - Healthy | Phase 1 | Completed | Actavis Inc. | 48 | 2003-06-01 | 2010-08-16 |
Anxiety Disorders (1) · Lymphoma, T-Cell, Cutaneous (1) · Mycosis Fungoides (1) · Pain (1) · Smoking (1)
Agile Therapeutics (2) · Scilex Pharmaceuticals, Inc. (2) · Actavis Inc. (1) · Falo, Louis, MD (1) · Frontier Biotechnologies Inc. (1) · Grünenthal GmbH (1) · Innoture Ltd (1) · Janssen Research & Development, LLC (1) · SocraTec R&D GmbH (1) · University of Houston (1) · ZARS Pharma Inc. (1)
United States (5) · Germany (3) · Belgium (1) · Canada (1) · China (1) · Netherlands (1) · United Kingdom (1)
Anthony R Godfrey, Pharm.D. (1) · Benoit Girard (1) · Dmitri Lissin, MD (1) · Elizabeth Garner, MD, MPH (1) · Elizabeth Garner, MD, PHD (1) · Michael J Zvolensky, Ph.D. (1) · Nicola X West (1) · Oleg E Akilov, MD, PhD (1) · Phillip LaStella, MD (1)
PMID 22943969, PMID 32606914, PMID 35696054
2018 (1), 2019 (1), R34DA031313 (1)